Watch for CLOVER data at ESMO (Oct 23-27) and ASCO GI (Jan 2027) for ORR, PFS, and OS updates. The ctDNA signal vs. real-world SOC is promising but preliminary — durability and regulatory path remain key catalysts. Monitor for any FDA feedback or partnership announcements.
Price Chart
Executive Summary
CytoDyn filed DEFA14A definitive additional proxy soliciting materials, which incorporate an 8-K announcing a CEO transition: Robert E. Hoffman (CFO since May 2025) becomes CEO effective October 20, 2026, replacing Dr. Jacob Lalezari, who moves to Head of Research and Translational Sciences. The filing also includes an investor presentation highlighting promising early ctDNA data from the Phase 2 CLOVER study in mCRC, showing a median 86% ctDNA decline at week 2 and statistically significant deeper molecular responses vs. real-world SOC cohorts. The CEO change is a routine succession event, but the bundled clinical data update is a notable positive catalyst for the leronlimab pipeline.
Key Facts
- Robert E. Hoffman appointed CEO effective Oct 20, 2026; Dr. Lalezari transitions to non-executive Head of Research and Translational Sciences.
- Hoffman's annual base salary increased to $525,000, bonus target to 50%, and granted options for 2,500,000 shares.
- CLOVER Phase 2 mCRC study: 96/96 (100%) screened patients tested CCR5+; median ctDNA decline of 86% at week 2 (n=28); 74.5% of patients with scans at week 8 show shrinkage or stable disease.
- CLOVER ctDNA responses statistically significantly deeper vs. Natera real-world Lonsurf+Bev cohort (median -93.22% vs. -55.19% at 0-4 weeks, p=0.0005).
- Three patients from CLOVER referred for curative-intent surgery.
- Company closed $17.5M and $16.2M financings in calendar 2026 to fund leronlimab development.
- Upcoming catalysts: ESMO (Oct 23-27, 2026) and ASCO GI (Jan 21-23, 2027) presentations with further CLOVER data; FDA communication planned for 2H 2026-1H 2027.
Financial Impact
No revenue or earnings data in filing; clinical-stage company with no approved products. Two recent financings totaling $33.7M closed in 2026.
Risk Factors
- CLOVER data is preliminary; final database lock and source verification pending — outcomes may change.
- CytoDyn is a clinical-stage company with no approved products; regulatory approval for leronlimab is uncertain.
- CEO transition may cause short-term execution risk despite orderly succession.
- Company trades OTCQB (CYDY) with limited liquidity and potential financing dilution risk.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001175680-26-000039 |
| Document: 0001175680-26-000039-index-headers.html | 0001175680-26-000039 |
| Document: 0001175680-26-000039-index.html | 0001175680-26-000039 |
| Document: 0001175680-26-000039.txt | 0001175680-26-000039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | DEFA14A | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2600 (+4.00%) |
Oct 19, 2026 6d ago | 8-K | $0.2500 $0.2500 | · 0.00% | ▼ −0.53% | $0.2600 (+4.00%) |
Oct 8, 2026 18d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.60% | $0.2600 (−30.00%) |
Oct 5, 2026 21d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2600 (−30.00%) |
Oct 5, 2026 21d ago | EFFECT | $0.2000 $0.2000 | · 0.00% | ▲ +0.55% | $0.2600 (−30.00%) |
Sep 25, 2026 4w ago | S-3 | $0.2200 $0.2000 | ▲ +9.09% | ▲ +8.91% | $0.2600 (−18.18%) |
Mar 5, 2026 33w ago | 8-K | $0.2400 $0.2300 | ▲ +4.17% | ▲ +2.85% | $0.2600 (−8.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers